Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
The Medicines Company's commercial lead for infection disease care talks about its breakthrough antidote for carbapenem-resistant enterobacteriaceae.
- Guidemark Health merges with three companies to form new agency
- Five things for pharma marketers to know: Monday, October 17, 2016
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Top 25 neurology products, based on 2016 sales forecasts
- New science drives biopharma interest in neurological conditions
- J&J exec calls California pricing measure 'misguided'
- Five things for pharma marketers to know: Monday, October 24, 2016